Company Overview
Company Type: Public Company
Website: innovotech.ca
Number of Employees: 14
Ticker: IOT (TSXV)
Year Founded: -


Business Description
Innovotech Inc. offers assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; MBEC Assay kit, a petri dish for biofilms, which are used for research and medical device testing of microbial biofilms; and AgreGuard, an antimicrobial for crop protection. It also provides antimicrobial contract research and antimicrobial testing; antimicrobial and anti-biofilm agents; antimicrobial and anti-biofilm materials; BEST assay testing; implanted medical devices; bacteriophage testing; and analytical services. The company serves customers in the areas of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal agricultural crop diseases, as well as disinfectants in food. Innovotech Inc. is headquartered in Edmonton, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
1.3
Market Capitalization
3.7
TEV/Total Revenue
2.6x
EBITDA
0.1
Total Enterprise Value
3.2
TEV/EBITDA
56.3x
EBIT
(0.1)
Cash & ST Invst.
0.5
P/Diluted EPS Before Extra
NM
Net Income
(0.1)
Total Debt
0.0
Price/Tang BV
3.5x
Capital Expenditure
(0.1)
Total Assets
1.1


Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Sep-27-2023

Key Professionals
Name
Title
Timourian, James 
Chairman, President & Secretary
Milne, Craig 
CEO & Director
Savage, Alan C.
CFO & Director
Boone, Tyler 
Chief Operating Officer
Nadworny, Patricia 
Chief Scientific Officer and Quality & Safety Director
Olson, Merle
Scientific Consultant

Key Board Members
Name
Title
Timourian, James 
Chairman, President & Secretary
Milne, Craig 
CEO & Director
Savage, Alan C.
CFO & Director
Farkas, Karen L.
Independent Director
Grobbelaar, Bernard 
Independent Director
Tam, Shong-Tak 
Independent Director
Wright, Julienne 
Independent Director


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
2011-94 Street Suite L131 | Edmonton, AB | T6N 1H1 | Canada
Phone: 780-448-0585   Fax: 780-424-0941

Current and Pending Investors
AVAC Ltd., Foundation Equity Corporation, Lonsdale Capital Corporation

Prior Investors
First Yellowhead Equities Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.10
Market Cap (mm)
3.7
Open
 0.10
Shares Out. (mm)
38.9
Previous Close
 0.10
Float %
57.6%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.10/ 0.10
Diluted EPS Excl. Extra Items
0.00
52 wk High/Low
 0.22/ 0.07
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0030
Avg 3M Dly Vlm (mm)
0.0097
Beta 5Y
0.86


 
Delayed Quote** | Last Updated on Sep-27-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Nou Life Sciences Inc.
Nou Life Sciences Inc., a nutraceutical company, develops antioxidants. The company was incorporated in 2006 and is based in Edmonton, Canada. As of August 25, 2023, Nou Life Sciences Inc. operates as a subsidiary of Innovotech Inc..

United States and Canada
Pharmaceuticals
-
-
-
Innovotech, Inc.
As of July 2, 2004, Innovotech, Inc. was acquired by MBEC BioProducts Inc. in a reverse merger transaction.

United States and Canada
Asset Management and Custody Banks
-
1.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-24-2020
Sep-02-2020
Private Placement
Target
Innovotech Inc. (TSXV:IOT)


0.29
Aug-18-2020
Aug-25-2023
Merger/Acquisition
Buyer
Nou Life Sciences Inc.
Innovotech Inc. (TSXV:IOT)

-
Apr-10-2017
May-02-2017
Private Placement
Target
Innovotech Inc. (TSXV:IOT)
Lonsdale Capital Corporation

0.29
Dec-4-2012
Feb-11-2013
Private Placement
Target
Innovotech Inc. (TSXV:IOT)


0.41
Apr-26-2012
Jun-30-2012
Private Placement
Target
Innovotech Inc. (TSXV:IOT)


0.51
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-25-2023
M&A Transaction Closings
Innovotech Inc. (TSXV:IOT) acquired 60% stake in Nou Life Sciences Inc..
Jul-17-2023
Executive/Board Changes - Other
Innovotech Inc. Appoints Julie Wright to Its Board of Directors
Jul-17-2023
Executive Changes - CEO
Innovotech Inc. Announces CEO Changes
May-15-2023
Product-Related Announcements
Innovosil -1 Antimicrobial Silver Works Against Candida Auris and Superbugs
Oct-25-2022
Executive/Board Changes - Other
Innovotech Inc. Announces Retirement of Gerard Tertzakian as Director


Advisors
Most Recent Auditor
D+H Group LLP


Most Recent Auditor
Dyke & Howard - D & H Group LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
ValuEngine, Inc.

Oct 02, 2023 06:19 AM
IOT
ValuEngine - Toronto Quantitative Stock Report for IOT
Reports
5
GlobalData

Sep 11, 2023 01:20 AM
IOT
Innovotech Inc (IOT.CVE) - Financial Analysis Review
Reports
69
GlobalData

Jun 09, 2023 03:16 AM
IOT
Innovotech Inc (IOT.CVE) - Financial Analysis Review
Reports
68
GlobalData

Mar 10, 2023 12:55 AM
IOT
Innovotech Inc (IOT.CVE) - Financial Analysis Review
Reports
66
GlobalData

Dec 13, 2022 12:26 AM
IOT
Innovotech Inc (IOT.CVE) - Financial Analysis Review
Reports
66
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Nov 01, 2022 06:00 PM
IOT
Rating Update for Innovotech Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 23, 2022 12:11 PM
IOT
Rating Update for Innovotech Inc
EPS Estimates*
3
GlobalData

Sep 13, 2022 04:30 AM
IOT
Innovotech Inc (IOT.CVE) - Financial Analysis Review
Reports
64
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 05, 2022 06:00 PM
IOT
Is There Long-Term Value in Innovotech Inc?
Ratings Change*
12
GlobalData

Jun 13, 2022 03:13 AM
IOT
Innovotech Inc (IOT.CVE) - Financial Analysis Review
Reports
64


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Savage, Alan C.

13,601,055

34.96

1.3

Aug-29-2023


Timourian Ph.D., James 

2,063,000

5.30

0.2

Aug-29-2023


Tam B.Sc.(Pharm), LL.B, Shong-Tak 

597,000

1.53

0.1

Sep-27-2023


Milne B.Sc., M.B.A., Ph.D., Craig 

160,000

0.41

0.0

Aug-29-2023


Grobbelaar C.A., CPA, CA, CPA, Bernard 

35,000

0.09

0.0

Aug-29-2023


Sassoun Investments Ltd

30,000

0.08

0.0

Aug-29-2023


Farkas M.B.A., M.S., Ph.D., Karen L.

15,000

0.04

0.0

Aug-29-2023


Tertzakian Ph.D., Gerard 

0

0.00

0.0

Aug-29-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Timourian Ph.D., James 
2,063,000
134,912
Savage, Alan C.
13,601,055
11,000
Tam B.Sc.(Pharm), LL.B, Shong-Tak 
597,000
5,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Tertzakian Ph.D., Gerard 
0
(917,724)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
AgreGuard, Agress, BESTplus Assay, BioFILM PA (Future), Biofilm Susceptibility Tests, Contract Research Services, InnovoSIL, MBEC Assay Kit, Sani-Lux


Upcoming Events
Date/Time
Type
Oct-10-2023 10:00 AM (MDT)
Shareholder/Analyst Calls
Oct-10-2023
Annual General Meeting
Nov-13-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-13-2023
-
Innovotech Inc. (TSXV:IOT)
SEDAR
Management Proxy Materials
72 KB
Sep-13-2023
-
Innovotech Inc. (TSXV:IOT)
SEDAR
Management Proxy Materials
223 KB
Sep-13-2023
-
Innovotech Inc. (TSXV:IOT)
SEDAR
Management Proxy Materials
510 KB
Aug-25-2023
-
Innovotech Inc. (TSXV:IOT)
SEDAR
News Releases
351 KB
Aug-15-2023
Jun-30-2023
Innovotech Inc. (TSXV:IOT)
SEDAR
Interim Financial Statements
126 KB
Aug-15-2023
-
Innovotech Inc. (TSXV:IOT)
SEDAR
News Releases
612 KB
Aug-07-2023
-
Innovotech Inc. (TSXV:IOT)
SEDAR
Notice of the Meeting and Record Date
313 KB
Aug-02-2023
-
Innovotech Inc. (TSXV:IOT)
SEDAR
News Releases
348 KB
Jul-17-2023
-
Innovotech Inc. (TSXV:IOT)
SEDAR
News Releases
452 KB
Jul-17-2023
-
Innovotech Inc. (TSXV:IOT)
SEDAR
News Releases
559 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Tam B.Sc.(Pharm), LL.B, Shong-Tak  (Independent Director)
Sep-27-2023
Class A Common Shares
3,000
290
Open Market Acquisition
0.51
Multiple
Tam B.Sc.(Pharm), LL.B, Shong-Tak  (Independent Director)
Sep-18-2023 - Sep-22-2023
Class A Common Shares
2,000
194
Open Market Acquisition
0.34
Multiple
-
Sep-18-2023
Class A Common Shares
1,000
97
Open Market Acquisition
-
Exchange Announcement
-
Sep-22-2023
Class A Common Shares
1,000
97
Open Market Acquisition
-
Exchange Announcement
Savage, Alan C. (CFO & Director)
Aug-25-2023
Class A Common Shares
9,000
867
Open Market Acquisition
0.07
Multiple
-
Aug-25-2023
Class A Common Shares
5,000
504
Open Market Acquisition
-
Exchange Announcement
-
Aug-25-2023
Class A Common Shares
4,000
363
Open Market Acquisition
-
Exchange Announcement
Savage, Alan C. (CFO & Director)
Aug-17-2023
Class A Common Shares
2,000
183
Open Market Acquisition
0.01
Multiple
Savage, Alan C. (CFO & Director)
May-10-2023
Class A Common Shares
10,000
1,028
Open Market Acquisition
0.07
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Timourian, James 
Chairman, President & Secretary
(780) 448-0585
780-424-0941
james.timourian@innovotech.ca
Milne, Craig 
CEO & Director
780-448-0585
780-424-0941

Savage, Alan C.
CFO & Director
(604) 220-4935
780-424-0941

Farkas, Karen L.
Independent Director
780-448-0585
780-424-0941

Grobbelaar, Bernard 
Independent Director
780-448-0585
780-424-0941

Tam, Shong-Tak 
Independent Director
(780) 423-8662
(780) 423-8522
dtam@parlee.com
Wright, Julienne 
Independent Director
780-448-0585
780-424-0941

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Timourian, James 
Chairman, President & Secretary
(780) 448-0585
780-424-0941
james.timourian@innovotech.ca
Milne, Craig 
CEO & Director
780-448-0585
780-424-0941

Savage, Alan C.
CFO & Director
(604) 220-4935
780-424-0941

Boone, Tyler 
Chief Operating Officer
780-448-0585
780-424-0941

Nadworny, Patricia 
Chief Scientific Officer and Quality & Safety Director
780-448-0585
780-424-0941

Olson, Merle
Scientific Consultant
780-448-0585
780-424-0941
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
